Oncology and Hematology

Episodes 161-176 of 532

HER2-Driven Strategies in Metastatic NSCLC
HER2-Driven Strategies in Metastatic NSCLC
MinuteCE®
HER2-Driven Strategies in Metastatic NSCLC
1.25 program credits
- Stephen Liu, MD
- Joshua K. Sabari, MD
- Susan Scott, MD
1.25 program credits
MET and Other Emerging Targets in Metastatic NSCLC
MET and Other Emerging Targets in Metastatic NSCLC
MinuteCE®
MET and Other Emerging Targets in Metastatic NSCLC
1.25 program credits
- Stephen Liu, MD
- Joshua K. Sabari, MD
- Susan Scott, MD
1.25 program credits
Emerging Therapeutic Developments in Non-Targetable Metastatic NSCLC
Emerging Therapeutic Developments in Non-Targetable Metastatic NSCLC
MinuteCE®
Emerging Therapeutic Developments in Non-Targetable Metastatic NSCLC
1.25 program credits
- Stephen Liu, MD
- Joshua K. Sabari, MD
- Susan Scott, MD
1.25 program credits
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
MinuteCE®
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
1.00 program credit
- John M. Kirkwood, MD
- Sapna Patel, MD
1.00 program credit
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
MinuteCE®
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
1.00 program credit
- John M. Kirkwood, MD
- Sapna Patel, MD
1.00 program credit
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
MinuteCE®
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
1.00 program credit
- Paolo A. Ascierto, MD
1.00 program credit
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
MinuteCE®
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
1.00 program credit
- Paolo A. Ascierto, MD
- Hussein Tawbi, MD, PhD
1.00 program credit
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
MinuteCE®
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
1.00 program credit
- Paolo A. Ascierto, MD
- Hussein Tawbi, MD, PhD
1.00 program credit
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
MinuteCE®
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
1.00 program credit
- Paolo A. Ascierto, MD
- Hussein Tawbi, MD, PhD
1.00 program credit
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
MinuteCE®
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
1.00 program credit
- Hussein Tawbi, MD, PhD
- Sapna Patel, MD
1.00 program credit
Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
MinuteCE®
Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
1.00 program credit
- Hussein Tawbi, MD, PhD
- Sapna Patel, MD
1.00 program credit
Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
MinuteCE®
Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
1.00 program credit
- Sapna Patel, MD
- John M. Kirkwood, MD
1.00 program credit
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
MinuteCE®
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
1.00 program credit
- Hussein Tawbi, MD, PhD
- Paolo A. Ascierto, MD
1.00 program credit
Clinical Decision-Making in Metastatic Breast Cancer: Optimizing Sequencing Choices
Clinical Decision-Making in Metastatic Breast Cancer: Optimizing Sequencing Choices
On the Frontlines of Metastatic Breast Cancer
Clinical Decision-Making in Metastatic Breast Cancer: Optimizing Sequencing Choices
- Ashley Baker, MSN, PMHNP
- Giancarlo Moscol, M.D.
DESTINY-Breast04 Findings: T-DXd and Quality of Life in HER2-Low Metastatic Breast Cancer
DESTINY-Breast04 Findings: T-DXd and Quality of Life in HER2-Low Metastatic Breast Cancer
On the Frontlines of Metastatic Breast Cancer
DESTINY-Breast04 Findings: T-DXd and Quality of Life in HER2-Low Metastatic Breast Cancer
- Marlene Mimi Maeusli, PhD.
Improving Metastatic Breast Cancer Care Through Integrated Palliative Support
Improving Metastatic Breast Cancer Care Through Integrated Palliative Support
On the Frontlines of Metastatic Breast Cancer
Improving Metastatic Breast Cancer Care Through Integrated Palliative Support
- Ryan Quigley